AGO1 Antibody (N-term) Blocking Peptide
€293.00
In stock
SKU
AC-BP6558a
Background:
AGO1 is a member of the Argonaute family of proteins which play a role in RNA interference. The protein is highly basic, and contains a PAZ domain and a PIWI domain. It may interact with dicer1 and play a role in short-interfering-RNA-mediated gene silencing.
Other Names: Protein argonaute-1, Argonaute1, hAgo1, Argonaute RISC catalytic component 1, Eukaryotic translation initiation factor 2C 1, eIF-2C 1, eIF2C 1, Putative RNA-binding protein Q99, AGO1, EIF2C1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6558a was selected from the N-term region of human AGO1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: Q9UL18
Gene ID: 26523
Gene Name: AGO1
Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Bio References:
Weinmann,L., Cell 136 (3), 496-507 (2009)Horikawa,Y., Clin. Cancer Res. 14 (23), 7956-7962 (2008)
AGO1 is a member of the Argonaute family of proteins which play a role in RNA interference. The protein is highly basic, and contains a PAZ domain and a PIWI domain. It may interact with dicer1 and play a role in short-interfering-RNA-mediated gene silencing.
Other Names: Protein argonaute-1, Argonaute1, hAgo1, Argonaute RISC catalytic component 1, Eukaryotic translation initiation factor 2C 1, eIF-2C 1, eIF2C 1, Putative RNA-binding protein Q99, AGO1, EIF2C1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6558a was selected from the N-term region of human AGO1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: Q9UL18
Gene ID: 26523
Gene Name: AGO1
Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Bio References:
Weinmann,L., Cell 136 (3), 496-507 (2009)Horikawa,Y., Clin. Cancer Res. 14 (23), 7956-7962 (2008)
| Is Featured? | No |
|---|
Write Your Own Review